<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559778</url>
  </required_header>
  <id_info>
    <org_study_id>NMTRC012</org_study_id>
    <nct_id>NCT02559778</nct_id>
  </id_info>
  <brief_title>Pediatric Precision Laboratory Advanced Neuroblastoma Therapy</brief_title>
  <acronym>PEDS-PLAN</acronym>
  <official_title>A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giselle SaulnierSholler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dell, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beat NB Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>K C Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Team Parker for Life</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of&#xD;
      using molecularly guided therapy in combination with standard therapy followed by a&#xD;
      Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO&#xD;
      maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">September 2032</completion_date>
  <primary_completion_date type="Anticipated">September 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days from start of therapy to date of first relapse</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>To measure the response of treatments chosen based on:&#xD;
• Event free survival (EFS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects that have a targeted agent chosen for treatment.</measure>
    <time_frame>2 years</time_frame>
    <description>At completion of the induction therapy, the investigators will determine feasibility of adding molecularly guided targeted therapy to standard of care chemotherapy. Feasibility will be defined as:&#xD;
Subject has a targeted agent identified&#xD;
Receives 75% of dosing of medications while on study protocol during cycles 3-6&#xD;
Subject is not removed from study due to targeted agent drug related toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects that receive 75% of dosing of medications while on study protocol during cycles 3-6.</measure>
    <time_frame>2 years</time_frame>
    <description>At completion of the induction therapy, the investigators will determine feasibility of adding molecularly guided targeted therapy to standard of care chemotherapy. Feasibility will be defined as:&#xD;
Subject has a targeted agent identified&#xD;
Receives 75% of dosing of medications while on study protocol during cycles 3-6&#xD;
Subject is not removed from study due to targeted agent drug related toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days that subjects remain alive</measure>
    <time_frame>3 years plus 5 years follow up</time_frame>
    <description>To measure the response of treatments chosen based on:&#xD;
Overall response rate (ORR) after induction therapy&#xD;
Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>To measure the response of treatments chosen based on:&#xD;
• Overall response rate (ORR) after induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 years</time_frame>
    <description>To compare toxicity effects of difluoromethylornithine (DFMO) in combination with Dinutuximab/GM-CSF/IL-2 and isotretinoin versus Dinutuximab/GM-CSF/IL-2 and isotretinoin alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of pain medicine required by Arm A versus Arm B</measure>
    <time_frame>3 years</time_frame>
    <description>To compare level of pain medicine needed during immunotherapy in patients receiving difluoromethylornithine (DFMO) in combination with Dinutuximab/GM-CSF/IL-2 and Isotretinoin versus those receiving Dinutuximab/GM-CSF/IL-2 and isotretinoin alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects required to go off therapy due to treatment-related adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>1 year</time_frame>
    <description>At completion of the induction therapy, the investigators will determine feasibility of adding molecularly guided targeted therapy to standard of care chemotherapy. Feasibility will be defined as:&#xD;
Subject has a targeted agent identified&#xD;
Receives 75% of dosing of medications while on study protocol during cycles 3-6&#xD;
Subject is not removed from study due to targeted agent drug related toxicity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Standard Immunotherapy without DFMO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Immunotherapy with DFMO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, all subjects will go on to receive DFMO BID for 730 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceritinib</intervention_name>
    <description>One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.</description>
    <arm_group_label>Standard Immunotherapy with DFMO</arm_group_label>
    <arm_group_label>Standard Immunotherapy without DFMO</arm_group_label>
    <other_name>Zykadia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.</description>
    <arm_group_label>Standard Immunotherapy with DFMO</arm_group_label>
    <arm_group_label>Standard Immunotherapy without DFMO</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.</description>
    <arm_group_label>Standard Immunotherapy with DFMO</arm_group_label>
    <arm_group_label>Standard Immunotherapy without DFMO</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.</description>
    <arm_group_label>Standard Immunotherapy with DFMO</arm_group_label>
    <arm_group_label>Standard Immunotherapy without DFMO</arm_group_label>
    <other_name>ZOLINZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFMO</intervention_name>
    <description>DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.</description>
    <arm_group_label>Standard Immunotherapy with DFMO</arm_group_label>
    <other_name>Eflornithine, α-difluoromethylornithine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part A:&#xD;
&#xD;
          1. Diagnosis: Subjects must have a diagnosis of neuroblastoma or ganglioneuroblastoma&#xD;
             (nodular or intermixed) verified by histology or demonstration of clumps of tumor&#xD;
             cells in bone marrow with elevated urinary catecholamine metabolites. Subjects with&#xD;
             the following disease stages at diagnosis are eligible, if they meet the other&#xD;
             specified criteria:&#xD;
&#xD;
             a) Subjects with newly diagnosed neuroblastoma with INSS Stage 4 are eligible with the&#xD;
             following: i. Age &gt; 18 months (&gt; 547 days) regardless of biologic features or ii. Age&#xD;
             12-18 months (365-547 days) with any of the following 3 unfavorable biologic features&#xD;
             (MYCN amplification, unfavorable pathology and/or DNA index = 1) or iii. MYCN&#xD;
             amplification (&gt; 4-fold increase in MYCN signals as compared to reference signals),&#xD;
             regardless of age or additional biologic features.&#xD;
&#xD;
             b) Subjects with newly diagnosed neuroblastoma with INSS Stage 3 are eligible with the&#xD;
             following: i. MYCN amplification (&gt; 4-fold increase in MYCN signals as compared to&#xD;
             reference signals), regardless of age or additional biologic features or ii. Age &gt; 18&#xD;
             months (&gt; 547 days) with unfavorable pathology, regardless of MYCN status.&#xD;
&#xD;
             c) Subjects with newly diagnosed neuroblastoma with INSS Stage 2A/2B with MYCN&#xD;
             amplification (&gt; 4-fold increase in MYCN signals as compared to reference signals),&#xD;
             regardless of age or additional biologic features.&#xD;
&#xD;
          2. Subjects must be age ≤ 21 years at initial diagnosis&#xD;
&#xD;
          3. Subjects must not have had prior systemic therapy except for localized emergency&#xD;
             radiation to sites of life-threatening or function-threatening disease and/or no more&#xD;
             than 1 cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (as&#xD;
             per P9641, A3961, ANBL0531, or similar) prior to determination of MYCN amplification&#xD;
             status and histology.&#xD;
&#xD;
          4. Specimens will be obtained only in a non-significant risk manner and not solely for&#xD;
             the purpose of investigational testing.&#xD;
&#xD;
          5. Ability to tolerate PBSC collection: No known contraindication to PBSC collection.&#xD;
             Examples of contraindications would include a weight or size less than that determined&#xD;
             to be feasible at the collecting institution, or a physical condition that would limit&#xD;
             the ability of the child to undergo apheresis catheter placement (if necessary) and/or&#xD;
             the apheresis procedure.&#xD;
&#xD;
             Part A and B both:&#xD;
&#xD;
          6. Adequate Cardiac Function Defined As:&#xD;
&#xD;
               1. Shortening fraction of ≥ 27% by echocardiogram, or&#xD;
&#xD;
               2. Ejection fraction of ≥ 50% by radionuclide evaluation or echocardiogram.&#xD;
&#xD;
          7. Adequate liver function must be demonstrated, defined as:&#xD;
&#xD;
             c. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age AND d. ALT (SGPT) &lt; 10&#xD;
             x upper limit of normal (ULN) for age&#xD;
&#xD;
          8. Subjects must have adequate renal function defined as a serum creatinine based on&#xD;
             age/gender as follows:&#xD;
&#xD;
             Age Maximum Serum Creatinine (mg/dL) Male Female 1 month to &lt; 6 months 0.4 0.4 6&#xD;
             months to &lt; 1 year 0.5 0.5 1 to &lt; 2 years 0.6 0.6 2 to &lt; 6 year 0.8 0.8 6 to &lt; 10&#xD;
             years 1 1 10 to &lt; 13 years 1.2 1.2 13 to &lt; 16 years 1.5 1.4&#xD;
&#xD;
             ≥ 16 years 1.7 1.4&#xD;
&#xD;
          9. A negative serum pregnancy test is required for female participants of child bearing&#xD;
             potential (≥13 years of age or after onset of menses)&#xD;
&#xD;
         10. Both male and female post-pubertal study subjects need to agree to use one of the more&#xD;
             effective birth control methods during treatment and for six months after treatment is&#xD;
             stopped. These methods include total abstinence (no sex), oral contraceptives (&quot;the&#xD;
             pill&quot;), an intrauterine device (IUD), levonorgestrol implants (Norplant), or&#xD;
             medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be&#xD;
             used, contraceptive foam with a condom is recommended.&#xD;
&#xD;
         11. Informed Consent: All subjects and/or legal guardians must sign informed written&#xD;
             consent. Assent, when appropriate, will be obtained according to institutional&#xD;
             guidelines.&#xD;
&#xD;
             Part B:&#xD;
&#xD;
         12. All patients must have a pathologically confirmed diagnosis of neuroblastoma, be age ≤&#xD;
             21 years at initial diagnosis, and classified as high risk by the criteria used by COG&#xD;
             or SIOPEN at the time of diagnosis. Exception: patients who are initially diagnosed as&#xD;
             non-high-risk neuroblastoma, but later converted (and/or relapsed) to high risk&#xD;
             neuroblastoma are also eligible.&#xD;
&#xD;
         13. Previous Therapy- subjects must fit into one of the strata categories listed in&#xD;
             section 10.5 to be eligible to enroll on Part B of this study.&#xD;
&#xD;
         14. Pre-enrollment tumor survey:&#xD;
&#xD;
             Prior to enrollment on Part B, a determination of mandatory disease staging must be&#xD;
             performed. Tumor imaging studies including CT or MRI, MIBG or PET, and VMA/HVA (PET&#xD;
             scan should be done for patients with prior disease that was MIBG non-avid). Bone&#xD;
             marrow aspirates and biopsies are required.&#xD;
&#xD;
             This disease assessment is required for eligibility and should be done preferably&#xD;
             within 2 weeks, but must be done within a maximum of 4 weeks before first dose of&#xD;
             study drug.&#xD;
&#xD;
         15. Timing- Enrollment to occur prior to Day + 120 post-transplant, preferably when the&#xD;
             subject is within 28 days after completing local radiation therapy (if given).&#xD;
&#xD;
        Exclusion Criteria (Part A and B)&#xD;
&#xD;
          1. Subjects who are 12-18 months of age with INSS Stage 4 and all stage 3 subjects with&#xD;
             favorable biologic features (ie, nonamplified MYCN, favorable pathology, and DNA index&#xD;
             &gt; 1) are not eligible.&#xD;
&#xD;
          2. Lactating females are not eligible unless they have agreed not to breastfeed their&#xD;
             infants.&#xD;
&#xD;
          3. Subjects receiving any investigational drug concurrently.&#xD;
&#xD;
          4. Subjects with any other medical condition, including but not limited to malabsorption&#xD;
             syndromes, mental illness or substance abuse, deemed by the Investigator to be likely&#xD;
             to interfere with the interpretation of the results or which would interfere with a&#xD;
             subject's ability to sign or the legal guardian's ability to sign the informed&#xD;
             consent, and subject's ability to cooperate and participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giselle Sholler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beat Childhood Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genevieve Bergendahl, MSN</last_name>
    <email>genevieve.bergendahl@atriumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Carpenter, MS</last_name>
    <email>Michael.Carpenter@atriumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Tate</last_name>
      <email>btate@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Alva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samuel Chimienti</last_name>
      <phone>602-546-0211</phone>
      <email>schimienti@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Francis Eshun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hall</last_name>
      <phone>501-364-2760</phone>
      <email>HallSF@archildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen Neville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland-</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Effie Bourgin</last_name>
      <email>EBourgin@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Anurag Agrawal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrzad Milburn</last_name>
      <phone>858-966-8155</phone>
    </contact>
    <investigator>
      <last_name>William Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Newton</last_name>
      <phone>860-545-9337</phone>
      <email>ANewton@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Michael Isakoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica El-Shami</last_name>
      <phone>321-841-8588</phone>
      <email>Jessica.El-Shami@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Don Eslin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Health</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Gray</last_name>
      <email>kigray@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Coleen McDonough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Siu, MPH</last_name>
      <phone>808-535-7169</phone>
      <email>andrea.siu@kapiolani.org</email>
    </contact>
    <investigator>
      <last_name>Randal Wada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Lukes</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Callie Wiskus</last_name>
      <email>wiskusca@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Eugenia Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Medical Group</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Maki</last_name>
      <email>sandy.maki@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Jason Canner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Thomas</last_name>
      <email>Jennifer.Thomas@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Ashok Raj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Steinbrecher</last_name>
      <phone>616-267-0334</phone>
      <email>Julie.Steinbrecher@helendevoschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Deanna Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Clinics on Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Haller</last_name>
      <phone>612-813-5913</phone>
      <email>courtney.haller@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Jawhar Rawwas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Dinkins</last_name>
      <phone>816-302-6893</phone>
      <email>MDinkins@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Keith August, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Maxwell, RN</last_name>
      <phone>314-268-4000</phone>
      <email>maxwellk@slu.edu</email>
    </contact>
    <investigator>
      <last_name>William Ferguson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chreyl Falls</last_name>
      <email>Cheryl.Falls@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Derek Hanson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Moore</last_name>
      <phone>980-442-2356</phone>
      <email>Abigail.Moore@atriumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Smith</last_name>
      <email>Lauren.Smith7@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Oesterheld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Randall Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron White</last_name>
      <email>AJWHITE@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Jason Glover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center and Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Treadway</last_name>
      <email>streadway@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Valerie Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Kraveka, MD</last_name>
      <phone>843-792-2957</phone>
    </contact>
    <investigator>
      <last_name>Jaqueline Kraveka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Blood and Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhea Robinson</last_name>
      <phone>512-628-1902</phone>
      <email>TXAUS-DL-SFCHemonc.research@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Virginia Harrod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Rivas</last_name>
      <phone>214-456-0004</phone>
      <email>michelle.rivas@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Ted Laetsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabrina Wigginton</last_name>
      <email>Sabrina.Wigginton@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Eric Lowe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://beatcc.org</url>
    <description>Beat Childhood Cancer Main Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Giselle SaulnierSholler</investigator_full_name>
    <investigator_title>Beat Childhood Cancer Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eflornithine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Ceritinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

